

CORPORATE EXECUTIVE COMMITTEE

The Corporate Executive Committee is responsible for managing Bachem worldwide and for implementing policies and strategies as defined by the Board of Directors.

ANNE-KATHRIN STOLLER

CHIEF EXECUTIVE OFFICER (CEO)

Anne-Kathrin Stoller joined Bachem in 2006. She has held several leadership roles, including Head of Business Development and Sales for Europe. She then served as Chief Marketing Officer and as a member of the Executive Committee for many years. In 2022, she became Chief Operating Officer for the Americas region and subsequently President of Bachem Americas, overseeing the company's operations in the US. On 1 January 2026, she took on the role of CEO at Bachem.

She studied chemistry in Hanover and Cambridge (UK) and earned her PhD in bioorganic chemistry from the University of Basel.



ALAIN SCHAFFTER

CHIEF FINANCIAL OFFICER (CFO)

Alain Schaffter joined Bachem in 2021 as CFO.

He started his career as an auditor at PricewaterhouseCoopers. In 2010, he moved into the pharmaceutical industry and became Head Group Finance of the listed Acino Group before joining Polyphor, a Basel-based biotech company, as CFO in 2016.

In early 2018, he started to work as a consultant for several companies in the Life Science Industry, supporting them in specific projects like Reporting, IFRS conversion or IPO preparation before he became Head Special Finance Projects at Solvias AG in August 2018. There he ran and coordinated the due diligence and deal related activities for the sale of Solvias Group to two Healthcare Investors, including process optimization in the areas of Accounting, Tax and Reporting. After completion of the transaction in June 2020, Alain Schaffter assumed, in addition to his existing role, the role as Head Finance M&A but also as CFO on an ad interim basis.

He served also as a Member of Group Executive Committees and held various mandates as Chairman of the Board of Trustees and as a member of the Board of Directors, of the Management Board and of the Audit Committee at subsidiaries worldwide.

Alain Schaffter holds a degree as a Swiss certified public accountant as well as a Federal certificate of higher vocational education and training for fiduciaries.



GÜNTHER LOIDL

CHIEF TECHNOLOGY OFFICER (CTO)

Guenther Loidl joined Bachem in 2000. He held several functions in Research and Development (R&D) and Active Pharmaceutical Ingredient Manufacturing and became Vice President R&D in 2012. Since 2015, he is CTO of the Bachem Group and a member of the Corporate Executive Committee.

He studied chemistry in Regensburg (Germany) and Leeds (UK) and obtained his doctorate under the supervision of Prof. Dr. Luis Moroder at the Max Planck Institute of Biochemistry in Martinsried (Germany).

He drives building the [oligonucleotide](#) business segment and is leading the Bachem [innovation](#) initiative.



TORSTEN WÖHR

CHIEF COMMERCIAL OFFICER (CCO)

Torsten Wöhr joined Bachem in 2017 as Sales Director for the generic API business and has led Bachem's oligonucleotide program since 2019.

Previously he held commercial leadership roles in various pharmaceutical manufacturing and life sciences companies in the United States and Europe.

He studied biochemistry & molecular biology at the Swiss Federal Institute of Technology (ETH) Zurich and holds a doctorate in bioorganic chemistry from the University of Lausanne/EPFL and a postgraduate degree in Industrial Engineering and Management, ETH Zurich.



HANS VAN HEES

CHIEF OPERATIONS OFFICER (COO)

Hans Van Hees joined Bachem in 2024 as COO Europe from Pharma Resource Group. Formerly, he served for more than 25 years in various manufacturing leadership roles at Johnson & Johnson and Janssen, including VP of Small Molecule API cluster at Janssen and VP of Global Technical Operations at Johnson & Johnson Consumer Health. He holds a Master's degree and a PhD in Chemistry, as well as an MBA from KU Leuven.

As COO, he is committed to the continued development of Bachem's production network and supporting strategic capacity expansions. His leadership ensures operational excellence across the sites during a pivotal phase of growth for the company.



BOARD OF DIRECTORS

The Board of Directors are responsible for defining Bachem's corporate strategy and are elected by the company shareholders.

[Click here >>](#)

NEWSLETTER REGISTRATION
GENERAL CONDITIONS
LEGAL STATEMENT
PRIVACY POLICY
IMPRINT
CONTACT

BACHEM

